NRIX — Nurix Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$26.45
+$0.41 (+1.57%)
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ. It is led by Arthur T. Sands M.D., Ph.D., based in 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005, with about 317 employees. Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Latest reported NRIX revenue for 2025-08-31 was $7.9M. Net income was -$86.4M. Revenue was down 82.1% from 2025-05-31 to 2025-08-31. NRIX currently screens at market cap $1.77B.
Use this NRIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NRIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NRIX SEC filings page. Lician reads the product cache first so this HTML stays unique to Nurix Therapeutics Inc even when a live quote feed is slow.
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX Key Statistics
Market Cap
$1.77B
Volume
551,836
Previous Close
$26.95
Day Range
$26.44 – $27.23
P/B Ratio
3.68
EPS
-$2.88
Revenue
$54.55M
Net Income
-$193.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-29.1%
Profit Margin
-354.9%
Employees
317
NRIX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $54.55M | $76.99M | $38.63M | $29.75M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$193.57M | -$143.95M | -$180.36M | -$117.19M |
| EPS (Diluted) | -$2.88 | -$2.65 | -$3.71 | -$2.73 |
Total Assets
$669.34M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$110.00M
Operating Cash Flow
-$172.58M
Free Cash Flow
$0.00
Nurix Therapeutics Inc Company Information
- CEO, President & Director
- Arthur T. Sands M.D., Ph.D.
- Headquarters
- 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Website
- www.nurixtx.com
- Phone
- 415 660 5320
- IPO / Founded
- 2020-07-24
- Sector
- Healthcare
- Industry
- Biotechnology